Kenvue falls ahead of Trump's 'important' announcement on autism findings

** Shares of Tylenol maker Kenvue KVUE.N fall 4% to $17.61

** U.S. President Donald Trump said on Saturday his administration would make announcement about its autism findings on Monday, declining to offer specifics

** The Wall Street Journal reported earlier this month that Health Secretary Robert F. Kennedy Jr. plans to announce that use of KVUE's popular over-the-counter pain medication, Tylenol, by pregnant women is potentially linked to autism, contrary to medical guidelines that say it is safe to use

** Kenvue has previously said it continues to believe that taking acetaminophen - the active ingredient in Tylenol - does not cause autism

** Up to last close, stock down 14.1% YTD